H. N. OLGUN Et Al. , "Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience," PEDIATRIC BLOOD & CANCER , vol.68, 2021
OLGUN, H. N. Et Al. 2021. Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience. PEDIATRIC BLOOD & CANCER , vol.68 .
OLGUN, H. N., Cecen, R. E., Ince, D., Onal, A., Baysal, B., Akyol, S., ... Ozdogan, O.(2021). Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience. PEDIATRIC BLOOD & CANCER , vol.68.
OLGUN, HATİCE Et Al. "Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience," PEDIATRIC BLOOD & CANCER , vol.68, 2021
OLGUN, HATİCE N. Et Al. "Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience." PEDIATRIC BLOOD & CANCER , vol.68, 2021
OLGUN, H. N. Et Al. (2021) . "Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience." PEDIATRIC BLOOD & CANCER , vol.68.
@article{article, author={HATİCE NUR OLGUN Et Al. }, title={Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience}, journal={PEDIATRIC BLOOD & CANCER}, year=2021}